City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy
City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy City Therapeutics, Inc., a biopharmaceutical leader in RNA interference (RNAi)-based medicine, has announced a strategic collaboration with global eye health leader Bausch + Lomb. The partnership…
Reports Positive Results from SP-624 qEEG and BNA™ Study by Arrivo BioVentures
Reports Positive Results from SP-624 qEEG and BNA™ Study by Arrivo BioVentures Arrivo BioVentures recently reported promising results from its SP-624-103 study, which evaluated the impact of SP-624’s novel epigenetic mechanism on neurological pathways. SP-624, a SIRT6 activator, may represent…
Compass Pathways Sets Price for Underwritten Offering
Compass Pathways Sets Price for Underwritten Offering Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on accelerating access to evidence-based mental health innovations, has announced the pricing of an underwritten offering. This offering includes 24,014,728 American Depositary Shares (ADSs)…
QIAGEN Enhances QIAcuity with Advanced Multiplexing Function
QIAGEN Enhances QIAcuity with Advanced Multiplexing Function QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a major enhancement to its QIAcuity digital PCR (dPCR) system, significantly boosting its performance. The upgrade more than doubles the number of targets that…
Free Testosterone Test: Revvity Receives FDA Clearance for First Automated Assay
Free Testosterone Test: Revvity Receives FDA Clearance for First Automated Assay Revvity, Inc. (NYSE: RVTY), a global leader in health science solutions, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s…
Pharma Innovator Frenelle Launches; CEO Missling Attends JPM 2025
Pharma Innovator Frenelle Launches; CEO Missling Attends JPM 2025 Frenelle Pharma, a dynamic new player in the pharmaceutical industry, is proud to announce its official launch. The company is leveraging its proprietary Faros™ long-acting injectable technology to revolutionize healthcare solutions…
Quanterix to Acquire Akoya Biosciences, Enhancing Protein Biomarker Detection
Quanterix to Acquire Akoya Biosciences, Enhancing Protein Biomarker Detection Quanterix Corporation (NASDAQ: QTRX), a leader in ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), renowned for its spatial biology innovations, have announced a definitive merger agreement. Under the agreement, Quanterix…
Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives
Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies for cancer, has highlighted recent achievements in its pipeline…
Pulse Biosciences Appoints Paul LaViolette as CEO
Pulse Biosciences Appoints Paul LaViolette as CEO Pulse Biosciences, Inc. (Nasdaq: PLSE), a leader in bioelectric medicine utilizing its cutting-edge Nanosecond Pulsed Field Ablation™ (nano-PFA™) technology, today announces the appointment of Paul A. LaViolette, the current Co-Chairman of the Board,…
Modivcare Secures $105 Million in Financing and Positions for Future Growth
Modivcare Secures $105 Million in Financing and Positions for Future Growth Modivcare Inc. (Nasdaq: MODV), a technology-enabled healthcare services company focused on integrated supportive care solutions, today announced several key initiatives to support its future growth. The company has secured…
Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics
Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics Marea Therapeutics, a clinical-stage biotechnology company focused on developing next-generation treatments for cardio-endocrine diseases, shared important updates on its progress as it prepares for the upcoming…
Heidelberg Engineering’s ANTERION® Gets FDA Clearance for Epithelial Thickness Module
Heidelberg Engineering’s ANTERION® Gets FDA Clearance for Epithelial Thickness Module Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, has announced the FDA clearance of its Epithelial Thickness Module, now available exclusively through the ANTERION® Cornea App.…